Bioxytran, Inc.

Bioxytran, Inc.

BIXT - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.27M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Bioxytran, Inc.Bioxytran, Inc.-0.7-91%--0.2
$-0.01

Current Fair Value

136.8% downside

Overvalued by 136.8% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$2.27 Million
Enterprise Value$2.95 Million
Earnings per Share$-0.02
Beta1.88
Outstanding Shares114,355,933

Return

Return on Equity90.84%ROE
Return on Assets-1346.43%
Return on Invested Capital64.05%

Valuation & Multiples

P/E Ratio-0.72P/E Ratio
PEG-0.2PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.02Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-0.93
Enterprise Value to Net Income-1
Total Debt to Enterprise0.29
Debt to Equity-0.17Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 20, 2026
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Bioxytran, Inc.

2 employees
CEO: David Platt

Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT...

Questions & Answers